---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-052702"
form_type: "8-K"
ticker: "CTKB"
cik: "0001831915"
company_name: "Cytek Biosciences, Inc."
filed_at: "2023-02-28T23:59:59+00:00"
generated_at: "2026-06-18T22:39:02.638026+00:00"
event_type: "m_and_a"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Cytek Biosciences completes $46.5M acquisition of Luminex flow cytometry assets

## Summary
- Closed acquisition of Luminex's flow cytometry and imaging business (Amnis, CellStream, Guava, Muse brands) on Feb 28, 2023.
- Purchase price approximately $46.5 million in cash, subject to customary adjustments at closing.
- Company assumed certain liabilities of the acquired business.
- Financial statements and pro forma information to be filed within 71 days after this 8-K.

## SEC filing metadata
- accession: 0001193125-23-052702
- form_type: 8-K
- ticker: CTKB
- cik: 0001831915
- company_name: Cytek Biosciences, Inc.
- filed_at: 2023-02-28T23:59:59+00:00
- event_type: m_and_a
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 2.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1831915/000119312523052702/0001193125-23-052702-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1831915/000119312523052702/d331452d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-052702
- JSON: https://secwatch.observer/filing/0001193125-23-052702.json
- Plain text: https://secwatch.observer/filing/0001193125-23-052702.txt

## Key facts
- M&A Transactions
  Cytek Biosciences, Inc. completed an acquisition involving Luminex Corporation for approximately $46.5 million in cash (closed 2023-02-28).
  - Action: acquisition
  - Counterparty: Luminex Corporation
  - Consideration: approximately $46.5 million in cash
  - Closing: 2023-02-28
  source text: under the Purchase Agreement. Pursuant to the Purchase Agreement, as consideration for the FCI Acquisition, the Company paid an aggregate purchase price of approximately $46.5 million in cash, subject to certain customary adjustments at closing, and assumed certain liabilities of the Business. The foregoing description of the FCI Acquisition and the Purchase
  evidence_url: https://www.sec.gov/Archives/edgar/data/1831915/000119312523052702/0001193125-23-052702-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.